Back to News
Market Impact: 0.12
SIBIONICS and PharmaSens Explore New Horizons for Automated Insulin Delivery at EASD 2026
Source: PRWeb
Healthcare & BiotechTechnology & Innovation
SiBionics presented its "See More, Act Earlier" diabetes-care vision at EASD 2026 in Milan, focused on connecting continuous sensing with future diabetes management. The presentation highlighted "See More: Beyond Glucose," but the available article text provides no clinical results, commercialization timeline, financial figures, or material product specifications.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
More News
- SoftBank’s Masayoshi Son Has Rare Cautionary Note on AI Safety
- Sen. Mitch McConnell closed a loophole in a hemp law he championed. Now a $28 billion THC industry that gets people high is fighting for survival
- Germany's Merz arrives in Kyiv to finalize drone deal, release aid
- Russia hits Kyiv bridge as Germany’s Merz visits Ukraine’s capital
- Germany’s Merz arrives in Kyiv to the sound of sirens and explosions
- Schneider Electric close to $20 bln deal of U.S. software maker PTC - report
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Vendor Landscape for Institutional Investment Teams
- AllMind Fixed Income Compass for October 2025: Navigating Policy Divergence and Political Risk